Showing 1,141 - 1,160 results of 121,722 for search '(( 2 e decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.89s Refine Results
  1. 1141
  2. 1142
  3. 1143
  4. 1144
  5. 1145
  6. 1146

    siRNA treatment decreases ADAMTS-1 nuclear pattern in MDA-MB-231 cells. by Suély V. Silva (3233223)

    Published 2016
    “…(D-E) Aggrecan Western blot after digestion. Lane 1: Aggrecan from bovine articular cartilage (300 nM); Lane 2: Aggrecan from bovine articular cartilage (300 nM) incubated with 30 μg of MDA-MB-231 nuclear fraction; Lane 3: 30 μg of MDA-MB-231 nuclear fraction. …”
  7. 1147

    A brief course of RAP treatment decreases markers of proliferation and increases markers of differentiation. by Karin M. Hardiman (555189)

    Published 2014
    “…<p><i>CDX2P-CreER<sup>T2</sup> Apc<sup>fl/fl</sup></i> mice were injected with TAM and monitored until polyposis was seen endoscopically, then the mice were treated with vehicle or RAP at 3 mg/kg concentration for periods of one, three, or five days (N = 5 per timepoint). …”
  8. 1148
  9. 1149
  10. 1150

    Oxytocin decreases postsynaptic CeA spontaneous GABAergic transmission and blocks presynaptic alcohol effects. by Brendan J. Tunstall (6593357)

    Published 2019
    “…<sup>#</sup>Significant difference between groups (<i>p</i> < 0.05). Amp, amplitude; CeA, central nucleus of the amygdala; EtOH, ethanol; Freq, frequency; mIPSC, miniature inhibitory postsynaptic current; OT, oxytocin; OTA, desGly-NH2-d(CH2)5[D-Tyr2,Thr4]OVT; sIPSC, spontaneous inhibitory postsynaptic current; TTX, tetrodotoxin.…”
  11. 1151
  12. 1152
  13. 1153
  14. 1154
  15. 1155
  16. 1156

    Decreased proliferation and increased apoptosis in <i>Mab21l2</i> mutant embryos. by Yohei Saito (180130)

    Published 2012
    “…<p>(A–F) BrdU assay on transverse paraffin sections of E11.5 WT and <i>Mab21l2</i> mutant (−/−) embryos. …”
  17. 1157
  18. 1158

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  19. 1159

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  20. 1160